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INTRODUCTION
Lately, the newly described interleukin-
37 has emerged as an important part of
the antiinflammatory system affecting
both innate and adaptive immunity. We
know that within the interleukin-1 (IL-1)
family, the proinflammatory members
are tightly regulated to avoid excessive
inflammation. Examples of this include
the potent blocking of IL-1α and IL1-β
by IL-1 receptor antagonist (1), IL-18
binding protein’s capacity to neutralize
IL-18 (2) and IL-36 receptor antagonist’s
ability to reduce IL-36 activity (3). How-
ever, IL-37, a new member of the IL-1
family, has unique properties because
this cytokine broadly suppresses the
function of other members of the IL-1
family as well as proinflammatory sig-
nals delivered by toll-like receptor
(TLR) agonists (reviewed in [4]). IL-37
itself appears to be under tight regula-
tory control, as steady-state levels of
mRNA are limited by an inherent insta-
bility sequence (5). Five transcript vari-
ants (IL-37a–e) have been described
with the largest, IL-37b containing five
of the six exons (6–10). In PBMCs, IL-37
protein is primarily expressed in mono-
cytic cells (11).
Similar to IL-1α and IL-33, IL-37 has
been shown to be active both extracellu-
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larly and intracellularly, where it is
translocated to the nucleus and sup-
presses TLR-agonist-induced cytokines
by a caspase-1-dependent mechanism
(12,13). In addition, neutralizing anti-
bodies to IL-37 have demonstrated an ef-
fect of extracellular IL-37, resulting in a
higher proinflammatory load (12).
Therefore, due to these antiinflammatory
and immunosuppressive functions of 
IL-37 and to the potential for a future
therapeutic use of this cytokine, diseases
dominated by excess inflammation are
becoming a subject of great interest. For
instance, studies have reported higher
levels of IL-37 expression in melanoma
patients, systemic lupus erythematosus,
colitis, rheumatoid arthritis, atopic der-
matitis and morbid obesity (14–19). In
addition, several studies are showing
correlation between both increased and
decreased amounts of IL-37 to the sever-
ity of the disease (reviewed in [20]). In a
mouse model, a marked protection
against LPS-induced shock was ob-
served with transgenic expression of
human IL-37 (IL-37tg) (17). In addition,
IL-37tg mice subjected to chemically-
 induced colitis exhibited a lower level 
of colonic inflammation, reduced IL-1β
and tumor necrosis factor alpha (TNFα)
production, but increased levels of IL-10;
effects of which proved to be myeloid-
derived rather than epithelial cell-de-
rived (16). IL-37 presumably mediates
suppression of acquired immunity by
the inhibition of dendritic cell matura-
tion, thereby affecting the functional link
between innate and adaptive immunity
(17,21).
HIV-1 infection is characterized by ex-
cess immune activation (22,23). Al-
though cART effectively suppresses
viral replication, persistent HIV-1-asso-
ciated immune activation is believed to
lead to impaired immune function and
premature immunologic aging, as well
as an increased risk of cardiovascular
disease and cancer (23–29). The under-
lying mechanisms are still poorly under-
stood, but the persistence of low-level
viremia despite effective cART and
translocation of microbial products,
such as LPS, across a compromised gas-
trointestinal mucosal surface has been
suggested to play important roles
(30–32).
Notably, HIV-1-infected patients with
inadequate reconstitution of the CD4+
T-cell compartment upon initiation of
cART, termed inadequate immunological
responders (IIRs), exhibit higher levels of
inflammatory biomarkers, greater T-cell
activation and increased mortality com-
pared with immunological responders
(33–40). Yet, how innate immune re-
sponses influence these pathological
processes remains unclear (41).
Thus, as HIV-1-associated inflamma-
tion negatively influences the health of
infected patients despite suppressive
cART and as IL-37 has emerged as a cy-
tokine with unique immune regulatory
effects, assessing IL-37 expression in the
context of chronic HIV-1 infection is an
important and unexplored area of re-
search. Therefore, we determined IL-37
mRNA expression, inflammation and
persistent HIV-1 DNA in an immunolog-
ical mixed cohort of chronically HIV-1-
infected patients.
MATERIALS AND METHODS
Study Design and Inclusion
This was a cross-sectional study in
which three groups of HIV-1-infected
patients were examined: (1) cART-naïve
with no history of antiretroviral treat-
ment; (2) cART-treated IIRs defined as
having CD4+ T-cell counts continuously
below 500 mm3 despite viral suppression
with plasma HIV RNA <50 copies/mL
for >3 years; (3) cART-treated immuno-
logical responders defined as having
reached a CD4+ T-cell count of >500 mm3
within 3 years of cART-induced viral
suppression with plasma HIV-1 RNA
<50 copies/mL. Healthy non–HIV-1-
 infected persons were included as con-
trol population. Data on CD4 T-cell
count, plasma HIV-1 RNA and use of
cART were obtained from hospital data-
bases and medical records. Subjects
known to be pregnant, coinfected with
Hepatitis B or C or diagnosed with any
autoimmune or autoinflammatory dis-
ease were excluded. The study was con-
ducted at the Department of Infectious
Diseases, Aarhus University Hospital,
Denmark. Written informed consent was
obtained from each participant. The
study was approved by The Regional
Research Ethics Committee for the Re-
gion of Midtjylland and The Danish
Data Protection Agency for the Region
of Midtjylland.
Serum and plasma samples were ob-
tained from each participant. Samples
were stored at –80°C until analyses.
PBMCs were isolated using Ficoll-Paque
PLUS (GE Healthcare, Pittsburgh, PA
USA) and stored at –180°C.
IL-37 mRNA in PBMCs
For each participant, total RNA was
extracted from 1 million PBMCs to stan-
dardize input, using the High Pure Isola-
tion kit (Roche, Basel, Switzerland) as de-
scribed by the manufacturer. Synthesis of
cDNA was performed using an Omnis-
cript Reverse Transcription kit (Qiagen,
Venlo, the Netherlands) with 5 μL RNA
as template and a final volume of 20 μL. 
A mixture of 1 μL oligo dT primer 
(0.4 μg/L) and 1 μL random hexamers
(0.4 μg/L) were used in addition to the
standard protocol. The gene U6 snRNA
(Table 1) was measured by real-time
polymerase chain reaction (RT-PCR) as a
quality control of the cDNA and for fur-
ther use as an endogenous normalization
control.
A nested-PCR containing two amplifi-
cation rounds was used to measure IL-37
levels in the cDNA samples. We used a
full-length cloned IL-37 cDNA transcript
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Table 1. Primer sequences.
Cytokine Forward (5′→3′) Reverse (5′→3′) Length
IL-37 (1 round) CTCCTGGGGGTCTCTAAAGG GATGAACCATCCGGGGTGAG 204 bp
U6 snRNA GCTTCGGCAGCACATATACTAAAA CGCTTCACGAATTTGCGTGTCAT 84 bp
in serial dilutions as positive control pro-
ducing a final standard curve. Nontem-
plate controls and RNA samples not re-
verse transcribed were run alongside
patient samples on every plate to ensure
optimal control for possible contamina-
tion. Patient samples were mixed on all
plates to ensure samples from each of the
four groups were represented in every
run.
The first amplification round was lim-
ited to 10 cycles with the following con-
ditions (GeneAmp PCR System 9700, Ap-
plied Biosystems [Thermo Fisher
Scientific Inc., Waltham, MA, USA]):
95°C for 10 min, 10 cycles of 94°C for
20 s, 55°C for 40 s and 72°C for 40 s and
maintained at 4°C. We used 5 μL of
cDNA from each participant completed
with a PCR mixture consisting of 25 μL
AmpliTaq Gold PCR Master Mix (Ap-
plied Biosystems [Thermo Fisher Scien-
tific]), 2 μL of each 20 μmol/L IL-37
primer (see Table 1) and 16 μL RNase
free water to complete a final reaction
volume of 50 μL. All samples were run in
duplicates. The IL-37 primer pair was de-
signed to cover each of the five isoforms
of IL-37(a–e). Once amplified, the prod-
uct was 204 bp, crossing the
exon(5)–exon(6) junction.
In the second round of nested-PCR,
we used an IL-37 FAM-labeled Taqman
Gene Expression Assay (Applied Biosys-
tems [Thermo Fisher Scientific]) cover-
ing all five isoforms. All samples from
the first round were assayed in dupli-
cates, making a total of quadruplicate
determinations per patient. The PCR-
mix consisted of 10 μL 2× TaqMan Gene
Expression MasterMix, 1 μL 20× TaqMan
Gene Expression Assay (Hs00367201m1,
Applied Biosystems [Thermo Fisher Sci-
entific]) and 5 μL RNase free water. 4 μL
template was added from the previous
amplification, making a final 20 μL reac-
tion volume. The RT-qPCR was per-
formed using the following conditions:
95°C for 10 min, 45 cycles of 95°C for
15 s and 60°C for 1 min on a Bio-Rad
CFX96 Real-Time system (Bio-Rad, Her-
cules, CA, USA). The relative ratio of
IL-37 mRNA in the PBMCs was deter-
mined by the Pfaffl method using a stan-
dard curve. All patient values were re-
lated to the U6 snRNA as the reference
control. Seventy-three patient samples
were analyzed. The missing data on the
last seven patients were due to a limited
amount of cells.
Stimulation of PBMCs
We investigated the induction of IL-37
mRNA in PBMCs in response to 24 h of
stimulation with LPS (100 ng/mL). Cryo -
preserved PBMCs were rapidly thawed
and rested 3 h at 37°C, 5% CO2 in com-
plete medium (RPMI 1640 supplemented
with 10% Hi-FBS, 1% L-glutamine and 1%
Penicillin-Streptomycin [Biowest, Nuaille,
France]) in 96-well plates (250,000 cells/
100 μL/well). After 3 h, quadruplicate
wells were stimulated with 100 μL of LPS
(final concentration 100 ng/mL) or con-
trol medium, resulting in a final volume
of 200 μL per well. After 24 h at 37°C, 5%
CO2, supernatants were collected, and the
PBMCs washed and lysed directly in lysis
buffer in the wells. The samples were
frozen at –80°C. The RNA was purified
using the High Pure Isolation kit (Roche).
cDNA and subsequent nested PCR were
carried out as above. Data are missing on
eight patients in the RPMI and six pa-
tients in the LPS stimulation due to a lim-
ited amount of cells.
Soluble Markers
We measured the levels of soluble
CD14, IL-6 and soluble CD163 in plasma.
sCD14 and IL-6 were quantified using
Quantikine High Sensitivity ELISA, both
from R&D Systems (Minneapolis, MN,
USA). Plasma levels of sCD163 were de-
termined using an in-house assay. This
sandwich ELISA assay is using an poly-
clonal rabbit anti-CD163 IgG as capture
antibody and a monoclonal anti-CD163
as detection, described in more details
previously (42). Data from one patient in
the sCD163 analysis were excluded as an
outlier.
T-Cell Markers
Cryopreserved PBMCs were rapidly
thawed and transferred to 13 mL cold
phosphate buffered saline solution (PBS).
After washing, 106 cells were resus-
pended in FACS tubes with a staining
buffer containing bovine serum albumin
and incubated in the dark for 20 min
with the following antibodies: α-CD3
conjugated PE-Cy7 (BD Biosciences, San
Jose, CA, USA), α-CD4 conjugated APC-
H7 (BD Biosciences) and α-CD38 conju-
gated PerCP-Cy5.5 (BioLegend, San
Diego, CA, USA). Samples were washed
with 2 mL FACS flow buffer (BD Bio-
sciences) and analyzed on a FACSCanto 2
(BD Biosciences). The CD3+CD4– popula-
tion was used as an approximation for
CD8+ cells. Monocyte percentages were
estimated with forward and side scatter.
Data were analyzed using FlowJo v.7.6.5
(Tree Star, Ashland, OR).
Total Viral Reservoir
The total viral reservoir was deter-
mined in IIRs and Responders as copies
of integrated HIV-1 DNA per 106 PBMCs
using quantitative PCR. The frequency of
cells carrying HIV-DNA was calculated
from a standard curve of serially diluted
DNA from 8E5 cells (43). Lower limit of
detection in the assay was defined as 
25 copies/106 PBMCs, below which the
quantification was not considered reli-
able. Patients with lower HIV-DNA 
levels were assigned a random value
around 25 ± 1.
Statistical Analysis
Characteristics for the groups were
compared using ordinary one-way anal-
ysis of variance (ANOVA) or Kruskall-
Wallis test. When only data from two
groups were available, Rank sum test
(Mann-Whitney) or Student t test were
used as appropriate. Differences in labo-
ratory results for the four groups were
compared using Holm-Sidak multiple
comparisons test or Dunn multiple com-
parisons test in relation to distribution of
data. Paired data were analyzed using
Wilcoxon signed rank test. Data distribu-
tion was assessed by inspection of his-
tograms and normal quantile–quantile
(q–q) plots. Pearson correlation and lin-
ear regression were used to explore cor-
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relations between parameters. Two-
tailed P values below 0.05 were consid-
ered significant. Statistical analyses and
graphical presentations were performed
using GraphPad Prism, version 6.0
(GraphPad Software, Inc., La Jolla, CA,
USA) and Stata 12 (StataCorp, College
Station, TX, USA).
All supplementary materials are available
online at www.molmed.org.
RESULTS
Study Population
We included a total of 60 HIV-1-infected
patients (20 cART-naïve, 20 IIRs and
20 responders) as well as 20 noninfected
healthy subjects. Their characteristics are
shown in Table 2.
Levels of IL-37 mRNA in PBMCs from
HIV-1-Infected Patients
The steady state, constitutive levels of
IL-37 mRNA expression per U6 copy in
PBMCs were significantly higher among
HIV-1-infected patients compared with
noninfected controls. The difference was
2.4-fold (p ≤ 0.01) in cART-naïve subjects,
3.9-fold (p ≤ 0.0001) in IIRs and 4.0-fold
(p ≤ 0.0001) in responders when com-
pared with the levels in noninfected con-
trols. However, there were no statistically
significant differences in IL-37 mRNA
levels between the HIV-1-infected groups
(Figure 1). There were no significant dif-
ferences in the proportions of monocytes
between the subgroups (see Table 2).
Further, when the levels of IL-37 mRNA
were normalized to the monocyte pro-
portion, we observed the same pattern of
IL-37 mRNA distribution as in Figure 1,
indicating that the increase in PBMC 
IL-37 mRNA reflected an increase in the
amount of IL-37 mRNA per monocyte
rather than increased numbers of mono-
cytes (Figure 2).
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Table 2. Characteristics for all participants.
cART-treated 
inadequate cART-treated Noninfected 
cART-naïve responders responders controls 
Characteristic (n = 20) (n = 20) (n = 20) (n = 20) P valuea
Age, years (IQRb) 40.5 (34.3–52.8) 52.0 (43.0–64.5) 46.5 (43.0–51.0) 47.5 (35.0–55.0) 0.08
Sex
Male, no. 17 14 12 16 —
Female, no. 3 6 8 4 —
CD4+ cell count inclusion date, median cells/μL (IQR) 555 (385–743) 320 (280–378) 790 (640–1000) — <0.0001
Nadir CD4+ cell count, median cells/μL (IQR) 480 (385–613) 63 (20–139) 197 (119–340) — <0.0001
HIV RNA level, median log(copies/mL) (IQR) 4.2 (3.6–5.0) — — — —
Duration of cART, median years (IQR) — 5.6 (4.4–7.2) 10.1 (7.7–14.5) — 0.0005
Previremic index, median log(copies/mL) (IQR) — 4.9 (4.3–6.1) 5.0 (4.7–5.8) — 0.96
Monocyte percentage, % (IQR) 18.9 (12.2–25.6) 22.4 (16.2–29.0) 19.4 (15.4–22.9) 20.2 (15.1–23.4) 0.48
aP values determined by ordinary ANOVA.
bIQR, interquartile range.
Figure 1. IL-37 mRNA levels in PBMCs of
HIV-1-infected patients. Levels of mRNA
per copies of U6 for each of the four pa-
tient groups (noninfected controls, cART-
naïve, IIRs and responders). The P value
above each group corresponds to the
comparison made to noninfected controls
using Holm-Sidak multiple comparisons
test. Depicted are group mean with stan-
dard error of the mean (SEM).
Figure 2. IL-37 mRNA levels in PBMCs of
HIV-1-infected patients normalized to
monocyte proportions. Levels of mRNA per
copies of U6 for each of the four patient
groups (noninfected controls, cART-naïve,
IIRs and responders), normalized to mono-
cyte percentages in the PBMCs. The
P value above each group corresponds to
the comparison made to noninfected
controls using Holm-Sidak multiple com-
parisons test. Depicted are group mean
with standard error of the mean (SEM).
IL-37 mRNA Response to LPS
Stimulation
Next, we examined the induction of
IL-37 mRNA in response to LPS stimula-
tion in PBMCs. After stimulation, all
HIV-1-infected groups showed signifi-
cantly higher levels of IL-37 mRNA as
compared with noninfected controls,
both with and without LPS. Though the
relative induction of IL-37 mRNA did
not differ between groups, the absolute
increase in IL-37 mRNA was higher in
the HIV-1-infected groups (Figure 3).
Also, the IIRs showed significantly
higher levels of IL-37 than the cART-
naïve group, when stimulated with LPS
(p ≤ 0.01). The IL-37 mRNA induction in
response to LPS stimulation compared
with media alone was statistically signifi-
cant in all groups, except for responders
(p = 0.07), using Wilcoxon signed rank
test (see Figure 3).
IL-37 mRNA in Relation to sCD14, IL-6
and sCD163
We observed significantly higher levels
of circulating sCD14 in IIRs compared
with noninfected controls. The other HIV-
1-infected groups showed higher levels
as well, though not significant (Table 3
and Figure 4A). Moreover, we identified
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Figure 3. IL-37 mRNA levels with- and without stimulation. Levels of mRNA per copies of
U6 both with and without simulation for each of the four patient groups: noninfected
(n = 19/20/20 [PBMC/RPMI/LPS]); cART-naïve (n = 15/19/18); IIRs (n = 20/14/14); and 
responders (n = 19/19/19). The P value corresponds to the comparison between the
LPS-stimulated cART-naïve and IIRs. The significance levels indicated by asterisks 
(**p < 0.01; ***p < 0.001; ****p < 0.0001) correspond to the comparison made to non -
infected controls all using Holm-Sidak multiple comparisons test. Depicted are group
mean with SEM.
Table 3. Laboratory results for all participants.
cART-treated Noninfected
cART-naïve inadequate cART-treated controls Overall
Characteristic (n = 20)a responders (n = 20)a responders (n = 20)a (n = 20)a P value
IL-37 mRNA:U6 ratio per 106 PBMCs unstimulated (SD) 0.080 (0.05) ** 0.129 (0.10) **** 0.134 (0.12) **** 0.033 (0.03) <0.0001
IL-37 mRNA:U6 ratio per 106 PBMCs stimulated with 0.559 (0.45) **** 0.815 (0.38) **** 0.658 (0.34) **** 0.140 (0.11) <0.0001
RPMI for 24 h (SD)
IL-37 mRNA:U6 ratio per 106 PBMCs stimulated with 0.759 (0.62) ** 1.372 (0.76) **** 1.198 (1.40) **** 0.210 (0.13) <0.0001
LPS 24h (SD)
sCD14 plasma, 106 pg/mL (SD) 4.27 (1.05) ns 4.91 (1.07) * 3.65 (0.80) ns 2.62 (0.35) 0.03
sCD163 plasma μg/mL (SD) 2.78 (1.30) *** 2.25 (0.91) * 1.66 (0.55) ns 1.52 (0.44) <0.0001
hsIL-6 plasma, pg/mL (SD) 3.65 (2.94) ns 3.13 (2.79) ns 3.43 (2.90) ns 2.35 (2.49) 0.17
CD38 positive CD4+ T cells (SD) 16.9 (6.5) ns 15.3 (9.1) ns 10.9 (4.3) ns 11.6 (4.9) 0.01
CD38 positive CD8+ T cells (SD) 21.3 (10.6) **** 7.0 (6.0) ns 3.1 (1.9) ns 3.7 (2.0) <0.0001
Total viral reservoir, HIV-DNA per 106 PBMCs (SD) — — 424.9 (623) — 582.6 (976) — — 0.95
SD, standard deviation.
aANOVA with multiple comparisons analysis. Asterisks (*) correspond to the level of significance in relation to noninfected controls: *: p ≤
0.05; **: p ≤ 0.01; ***: p ≤ 0.001; ****: p ≤ 0.0001; ns: p > 0.05. Right column corresponds to the overall comparison.
a statistically significant positive correla-
tion between IL-37 mRNA and sCD14 
(p = 0.03; Figure 4B). Levels of sCD163
were significantly higher in cART-naïve
and IIRs compared with noninfected con-
trols (p ≤ 0.001; p ≤ 0.05), with the highest
levels in the cART-naïve group. The
cART-naïve group exhibited significantly
higher levels than the responders (p ≤
0.01) (see Table 3 and Figure 5A). As ex-
pected, sCD163 correlated with sCD14 
(p = 0.03), but there was no correlation
between sCD163 and IL-37 mRNA in
PBMCs (Figure 5B). We found a 1.4-fold
higher level of IL-6 in the plasma of 
HIV-1-infected individuals compared
with noninfected controls, however,
using multiple comparisons, no individ-
ual significant differences were observed
between the groups (see Table 3). In con-
trast to sCD14, there was no correlation
between circulating IL-6 and mRNA lev-
els of IL-37 in PBMCs (p = 0.10).
IL-37 and T-Cell Activation
To investigate T-cell activation, we an-
alyzed the expression of CD38 on CD4+
and CD8+ T cells. As shown in Table 3,
CD38 expression (both in CD4+ and
CD8+ T cells) followed the pattern: cART-
naïve > IIRs > noninfected controls > re-
sponders. We observed no correlation be-
tween IL-37 mRNA levels and CD38 ex-
pression when assessed in the total T-cell
pool or in individual T-cell subtype (Sup-
plementary Figures S1, S2).
IL-37 mRNA and the Size of the Total
Viral Reservoir
We identified a significant positive cor-
relation between the size of the total viral
reservoir as measured by HIV-1 DNA
and IL-37 mRNA levels in the PBMCs.
This association was present for both
LPS-induced IL-37 mRNA expression
and unstimulated IL-37 mRNA expres-
sion (p < 0.0001 and p = 0.04; Figures 6A,
B). There was no difference in HIV-1
DNA per 106 PBMCs between IIRs and
responders (436.1, [95% CI: 148–724] for
IIRs and 591.1, [95% CI: 137–1046] for re-
sponders; p = 0.95).
DISCUSSION
To our knowledge, this study is the
first to investigate the expression of IL-37
in HIV-1 infection. That the observed in-
creased expression of IL-37 could play a
regulatory role in HIV-1 by limiting in-
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Figure 5. Levels of sCD163 in plasma and correlation with IL-37 mRNA. (A) Levels of sCD163
in plasma for each of the four patient groups (noninfected controls, cART-naïve, IIRs and
responders). The P value above each group corresponds to the comparison made to
noninfected controls using Dunn’s multiple comparisons test (ns, nonsignificant). Depicted
are group mean with SEM. (B) Levels of sCD163 in plasma compared with the levels of 
IL-37 mRNA in PBMCs using Pearson correlation (r = –0.06)
Figure 4. Levels of sCD14 in plasma and correlation with IL-37 mRNA. (A) Levels of sCD14 in
plasma for each of the four patient groups (noninfected controls, cART-naïve, IIRs and re-
sponders). The P value above each group corresponds to the comparison made to non-
infected controls using Holm-Sidak multiple comparisons test (ns; nonsignificant). Depicted
are group mean with SEM. (B) Levels of sCD14 in plasma compared with the levels of IL-37
mRNA in PBMCs using Spearman correlation (r = 0.25).
flammation is consistent with the role of
other antiinflammatory members of the
IL-1 family. For instance, elevated levels
of the IL-1 receptor antagonist, soluble
IL-1 receptor type 2 and IL-18 binding
protein are often present in autoimmune
and autoinflammatory diseases, and
serve as indicators of disease severity.
We know that IL-37 is immunosuppres-
sive and that it imposes a tolerogenic state
on dendritic cells (21). However, trying to
link the increased expression of IL-37 in
HIV-1 as a causal factor for the immuno-
suppression of the disease does require
consideration for the antiinflammatory ef-
fect of the cytokine. In a recent study on
obesity-related inflammation, a higher ex-
pression of IL-37 mRNA in adipose tissue
provided better insulin sensitivity, mean-
ing a beneficial role for greater expression
of IL-37 (44). Both concepts must be kept
in mind, therefore, in the present study in
HIV-1-infected patients.
The excessive inflammation in HIV-1
infection has been proposed to be associ-
ated with persistent but low level
viremia as well as with translocation of
microbial products, such as LPS, from a
compromised gastrointestinal mucosal
barrier (30,45–47). Since LPS stimulation
of TLR4 on monocytes is an important
signal for IL-37 production, acting by sta-
bilizing IL-37 mRNA (5), we set out to
study this. Clearly, LPS stimulation, as
well as RPMI alone, upregulated IL-37
mRNA production to higher levels
among HIV-1-infected patients compared
with noninfected controls. Interestingly
the relative inductions in all four groups
were comparable, which could indicate
that the capability of inducing IL-37
mRNA in HIV-1-infected patients is still
intact. Thus the higher absolute levels
could be a sign of a decreased capability
of producing functional protein and/or a
higher proinflammatory response to LPS
in the HIV-1-infected patients. In this
context, the significant higher level of IL-
37 mRNA in the IIRs, but not the respon-
ders, compared with cART-naïve could
be related to both outlined concepts.
Looking at the effect of plasma viral
load on IL-37 mRNA, we did not observe
any changes in the levels between the
cART-naïve and cART-treated patients in
unstimulated PBMCs, indicating that in-
creased viral replication does not affect
IL-37 transcription. Instead we propose
that increased IL-37 expression may be
due to ongoing low-level inflammation
affecting the monocytes, and that despite
effective cART, this inflammation is still
not fully suppressed in terms of upregu-
lated IL-37 transcription. The relevance
for HIV-1-infected patients is that in-
creased IL-37 expression may contribute
to the immunosuppression of the dis-
ease, for example, response to neoanti-
gens, to recall antigens or to the mainte-
nance of cytotoxic T cells targeting
HIV-1. Though whether IL-37 is a
 disease-specific biomarker in HIV-1 that
predicts clinical outcomes remains an
open question.
Another property of IL-37 that may af-
fect HIV-1-infected subjects is the increase
in IL-10 and TGFβ. In mice transgenic for
human IL-37, increased production of IL-
10 has been reported in models of colitis
(16) and endotoxemia (48). In addition,
TGFβ induces IL-37 production and is
upregulated in HIV (49) and, more specif-
ically, a high production of TGFβ in re-
sponse to HIV has been observed to in-
hibit an appropriate IFNγ response (50).
The antiinflammatory and immunosup-
pressive properties of these cytokines
therefore seem closely related, although
the precise interactions and their possible
relations to HIV-1 pathogenesis require
further experiments.
In this study, we observed a positive
correlation between sCD14 and IL-37
mRNA. As sCD14 has formerly been as-
sociated with increased morbidity and
mortality in HIV-1 infection (51–53), the
correlation between IL-37 mRNA pro-
duction and sCD14 levels might also in-
dicate an important role of IL-37 in re-
sponse to the ongoing low-level
inflammation on cART, although this
correlation was weak and obviously lim-
iting the conclusions to be made here.
Signs of a prognostic relevance for this
cytokine does require further attention in
future studies as a faulty inflammatory
regulation has been observed to have
prognostic implications with other mem-
bers of the IL-1 family in different condi-
tions (54–56).
That sCD14 burden is not lower in
cART-naïve and cART-treated subjects
mimics the pattern of IL-37 mRNA, that
is, monocyte activation is not directly af-
fected by plasma viral load. Instead,
other mechanisms such as microbial
translocation from the intestines con-
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Figure 6. Correlation between the total viral reservoir and IL-37 mRNA in PBMCs. Levels 
of IL-37 mRNA compared with the size of the total viral reservoir (HIV-1 DNA copies/ 106
PBMCs) both with (B) and without (A) LPS stimulation. P values corresponds to the corre-
lation between IL-37 mRNA and HIV-1 DNA using Spearman correlation (r = 0.33 [PBMC];
r = 0.67 [LPS]).
tribute to the chronic inflammatory state
as observed previously (57).
In line with previous reports, we ob-
served higher levels of sCD163 among
HIV-1-infected patients compared with
noninfected controls, though not signifi-
cant for the responders (58). However,
sCD163 did not correlate with IL-37
mRNA in this cross-sectional cohort. This
finding could reflect sCD163’s linkage as
a more macrophage-specific activation
marker (59).
Interestingly, we observed a positive
correlation between IL-37 mRNA expres-
sion levels and the size of the total viral
reservoir as measured by HIV-1 DNA in
PBMCs. It is still unclear whether the
size of the total viral reservoir is a pre-
dictor of, or a causal factor in, chronic in-
flammation. Whereas a recent study re-
ported a consistent association between
cell-based measures of viral persistence
and immune activation (60), a similar in-
vestigation did not find any significant
correlation between the levels of HIV-1
DNA in PBMCs and measures of im-
mune activation (61). Whether there is a
direct relationship between reservoir size
and IL-37 remains elusive because the
correlation is based on a limited amount
of patients, but we speculate that IL-37
mRNA production and total viral load in
this context both might be indicators of
immune dysfunction.
This study is limited in the nature of a
cross-sectional study preventing any con-
clusions on causality. Secondly, as we
measured all isoforms of IL-37 mRNA
collectively in this study, an isoform-spe-
cific analysis could have provided fur-
ther insight into the internal regulation
of IL-37. Thirdly, although these initial
findings are based primarily on the
amount of mRNA, and therefore not the
functional cytokine, other studies in
human PBMCs and in mice transgenic
for human IL-37, have shown that the IL-
37 protein is synthesized under inflam-
matory conditions such as TLR stimula-
tion (12,17). We, and others, have
observed considerable variation using
the Adipogen IL-37 ELISA for (EDTA)
plasma and serum levels in a cohort of
healthy human subjects (ages 20 to 72).
In addition, we observed an inability of
the ELISA to detect IL-37 in LPS-
 stimulated monocyte supernatants and
lysates, with the same samples being
positive on a validated Western blotting
with the same antibody used in the
ELISA. Therefore, we must conclude that
levels of mRNA are the most reliable
data at present to evaluate the cytokine.
Lastly, we defined IIRs and responders
based on the available literature (33,34).
However, other studies have used lower
cutoffs of CD4+ T-cell counts to define
those who have been termed immuno-
logical nonresponders (40,62) as a sub-
group of the IIRs. This reduces the im-
munological proximity between the
groups and is likely to enhance differ-
ences between these subgroups of HIV-1
patients.
In conclusion, steady-state levels of
IL-37 mRNA in PBMCs of HIV-1-
 infected individuals, both with and
without LPS stimulation, were signifi-
cantly higher than in noninfected con-
trols. IL-37 mRNA correlated positively
with circulating levels of the monocyte
inflammatory marker sCD14, which
could suggest a functional link between
monocyte activation and IL-37. More-
over, a significant positive correlation
between the size of the HIV-1 reservoir
and mRNA levels of IL-37 in PBMCs
was observed. Collectively, these data
add to the understanding of the inflam-
matory processes observed with chronic
HIV-1 infection and its possible relation
to IL-37.
ACKNOWLEDGMENTS
We would like to acknowledge all the
participating patients who made this
study possible. Special gratitude is also
extended for Lene Svinth Jøhnke and
Erik Hagen for their help and guidance
in the lab, and to the medical laboratory
assistants in Q-lab. The work was sup-
ported by The Danish Research Council
(FSS) by grant 0602-02300B to M Tolstrup
and by the Augustinusfonden, Familien
Hede Nielsens Fund and Ulla og Mogens
Folmer Andersens Fund to JF Højen.
DISCLOSURE
The authors declare they have no com-
peting interests as defined by Molecular
Medicine, or other interests that might be
perceived to influence the results and
discussion reported in this paper.
REFERENCES
1. Arend WP. (2002) The balance between IL-1 and
IL-1Ra in disease. Cytokine Growth Factor Rev.
13:323–40.
2. Novick D, et al. (1999) Interleukin-18 binding
protein: a novel modulator of the Th1 cytokine
response. Immunity. 10:127–36.
3. Towne JE, et al. (2011) Interleukin-36 (IL-36) lig-
ands require processing for full agonist (IL-36α,
IL-36β, and IL-36γ) or antagonist (IL-36Ra) activ-
ity. J Biol. Chem. 286:42594–602.
4. Dinarello CA, Bufler P. (2013) Interleukin-37.
Semin. Immunol. 25:466–8.
5. Bufler P, Gamboni-Robertson F, Azam T, Kim SH,
Dinarello CA. (2004) Interleukin-1 homologues IL-
1F7b and IL-18 contain functional mRNA instabil-
ity elements within the coding region responsive
to lipopolysaccharide. Biochem. J. 381:503–10.
6. Busfield SJ, et al. (2000) Identification and gene
organization of three novel members of the IL-1
family on human chromosome 2. Genomics.
66:213–6.
7. Kumar S, et al. (2002) Interleukin-1F7B (IL-1H4/
IL-1F7) is processed by caspase-1 and mature IL-
1F7B binds to the IL-18 receptor but does not in-
duce IFN-gamma production. Cytokine. 18:61–71.
8. Pan G, et al. (2001) IL-1H, an interleukin 1-related
protein that binds IL-18 receptor/IL-1Rrp. Cy-
tokine. 13:1–7.
9. Smith DE, et al. (2000) Four new members ex-
pand the interleukin-1 superfamily. J. Biol. Chem.
275:1169–75.
10. Taylor SL, Renshaw BR, Garka KE, Smith DE,
Sims JE. (2002) Genomic organization of the in-
terleukin-1 locus. Genomics. 79:726–33.
11. Bufler P, et al. (2002) A complex of the IL-1 ho-
mologue IL-1F7b and IL-18-binding protein re-
duces IL-18 activity. Proc. Natl. Acad. Sci. U. S. A.
99:13723–8.
12. Bulau AM, et al. (2014) Role of caspase-1 in nu-
clear translocation of IL-37, release of the cy-
tokine, and IL-37 inhibition of innate immune re-
sponses. Proc. Natl. Acad. Sci. U. S. A. 111:2650–5.
13. Sharma S, et al. (2008) The IL-1 family member
7b translocates to the nucleus and down-regu-
lates proinflammatory cytokines. J. Immunol.
180:5477–82.
14. Luo Y, et al. (2013) IL-37, an inhibitor of innate
and adaptive immunity, is elevated in the blood
of melanoma patients [abstract]. Pigment Cell
Melanoma Res. 26:951.
15. Song L, et al. (2012) Glucocorticoid regulates
interleukin-37 in systemic lupus erythemato-
sus. J. Clin. Immunol. 33:111–7.
16. McNamee EN, et al. (2011) Interleukin 37 expres-
3 4 4 |  H Ø J E N  E T  A L .  |  M O L  M E D  2 1 : 3 3 7 - 3 4 5 ,  2 0 1 5
I L - 3 7  m R N A  I N  C H R O N I C  H I V - 1  I N F E C T I O N
sion protects mice from colitis. Proc. Natl. Acad.
Sci. U. S. A. 108:16711–6.
17. Nold MF, et al. (2010) IL-37 is a fundamental 
inhibitor of innate immunity. Nat. Immunol.
11:1014–22.
18. Fujita H, Inoue Y, Seto K, Komitsu N, Aihara M.
(2012) Interleukin-37 is elevated in subjects with
atopic dermatitis. J. Dermatol Sci. 69:173–5.
19. Moschen AR, et al. (2011) Adipose and liver ex-
pression of interleukin (IL)-1 family members in
morbid obesity and effects of weight loss. Mol.
Med. 17:840–5.
20. Dinarello CA, Bufler P. (2013) Interleukin-37.
Semin. Immunol. 25:466–8.
21. Luo Y, et al. (2013) IL-37 suppresses contact hy-
persensitivity by inducing tolerogenic dendritic
cells. Cytokine. 63:283.
22. Hunt PW. (2012) HIV and inflammation: mecha-
nisms and consequences. Curr. HIV/AIDS Rep.
9:139–47.
23. Neuhaus J, et al. (2010) Markers of inflamma-
tion, coagulation, and renal function are ele-
vated in adults with HIV infection. J. Infect. Dis.
201:1788–95.
24. Kuller LH, et al. (2008) Inflammatory and coagu-
lation biomarkers and mortality in patients with
HIV infection. PLoS Med. 5:e203.
25. Currier JS, et al. (2008) Epidemiological evidence
for cardiovascular disease in HIV-infected pa-
tients and relationship to highly active antiretro-
viral therapy. Circulation. 118:e29–35.
26. Grulich AE, van Leeuwen MT, Falster MO, Vajdic
CM. (2007) Incidence of cancers in people with
HIV/AIDS compared with immunosuppressed
transplant recipients: a meta-analysis. Lancet.
370:59–67.
27. Marin B, et al. (2009) Non-AIDS-defining deaths
and immunodeficiency in the era of combination
antiretroviral therapy. AIDS. 23:1743–53.
28. Deeks SG, Phillips AN. (2009) HIV infection, an-
tiretroviral treatment, ageing, and non-AIDS re-
lated morbidity. BMJ. 338:a3172.
29. Sogaard OS, et al. (2008) Hospitalization for
pneumonia among individuals with and without
HIV infection, 1995–2007: a Danish population-
based, nationwide cohort study. Clin Infect. Dis
47:1345–53.
30. Brenchley JM, et al. (2006) Microbial translocation
is a cause of systemic immune activation in
chronic HIV infection. Nat. Med. 12:1365–71.
31. Mavigner M, et al. (2009) HIV-1 residual viremia
correlates with persistent T-cell activation in poor
immunological responders to combination anti-
retroviral therapy. PloS One. 4:e7658.
32. Ostrowski SR, Katzenstein TL, Pedersen BK, Ger-
stoft J, Ullum H. (2008) Residual viraemia in
HIV-1-infected patients with plasma viral load ≤
20 copies/ml is associated with increased blood
levels of soluble immune activation markers.
Scand. J. Immunol. 68:652–60.
33. Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD.
(2012) Incomplete immune recovery in HIV in-
fection: mechanisms, relevance for clinical care,
and possible solutions. Clin. Dev. Immunol.
2012:670957.
34. Kaufmann GR, et al. (2005) Characteristics, deter-
minants, and clinical relevance of CD4 T cell re-
covery to < 500 cells/microL in HIV type 1-in-
fected individuals receiving potent antiretroviral
therapy. Clin. Infect. Dis. 41:361–72.
35. Piketty C, et al. (1998) Discrepant responses to
triple combination antiretroviral therapy in ad-
vanced HIV disease. AIDS. 12:745–50.
36. Piconi S, et al. (2010) Immune activation, apopto-
sis, and Treg activity are associated with persist-
ently reduced CD4+ T-cell counts during anti-
retroviral therapy. AIDS. 24:1991–2000.
37. Baker JV, et al. (2008) Poor initial CD4+ recovery
with antiretroviral therapy prolongs immune de-
pletion and increases risk for AIDS and non-
AIDS diseases. J. Acquir. Immune Defic. Syndr.
48:541–6.
38. Gutierrez F, et al. (2008) Patients’ characteristics
and clinical implications of suboptimal CD4 T-
cell gains after 1 year of successful antiretroviral
therapy. Curr. HIV Res. 6:100–7.
39. Nakanjako D, et al. (2011) High T-cell immune ac-
tivation and immune exhaustion among individ-
uals with suboptimal CD4 recovery after 4 years
of antiretroviral therapy in an African cohort.
BMC Infect. Dis. 11:43.
40. Lederman MM, et al. (2011) Immunologic failure
despite suppressive antiretroviral therapy is re-
lated to activation and turnover of memory CD4
cells. J. Infect. Dis. 204:1217–26.
41. Benecke A, Gale M, Jr., Katze MG. (2012) Dynam-
ics of innate immunity are key to chronic im-
mune activation in AIDS. Curr. Opin. HIV AIDS.
7:79–85.
42. Moller HJ, Hald K, Moestrup SK. (2002) Charac-
terization of an enzyme-linked immunosorbent
assay for soluble CD163. Scand. J. Clin. Lab. In-
vest. 62:293–9.
43. Winckelmann AA, et al. (2013) Administration of
a toll-like receptor 9 agonist decreases the provi-
ral reservoir in virologically suppressed HIV-in-
fected patients. PloS One. 8:e62074.
44. Ballak DB, et al. (2014) IL-37 protects against obe-
sity-induced inflammation and insulin resistance.
Nature Commun. 5:4711.
45. Llibre JM, et al. (2012) Treatment intensification
with raltegravir in subjects with sustained HIV-1
viraemia suppression: a randomized 48-week
study. Antivir. Ther. 17:355–64.
46. Brenchley JM, Price DA, Douek DC. (2006) HIV
disease: fallout from a mucosal catastrophe? Nat.
Immunol. 7:235–9.
47. Marchetti G, Tincati C, Silvestri G. (2013) Micro-
bial translocation in the pathogenesis of HIV in-
fection and AIDS. Clin. Microbiol. Rev. 26:2–18.
48. van de Veerdonk FL, et al. (2014) Protective host
defense against disseminated candidiasis is im-
paired in mice expressing human interleukin-37.
Front. Microbiol. 5:762.
49. Wiercinska-Drapalo A, Flisiak R, Jaroszewicz J,
Prokopowicz D. (2004) Increased plasma trans-
forming growth factor-beta1 is associated with
disease progression in HIV-1-infected patients.
Viral Immunol. 17:109–13.
50. Garba ML, Pilcher CD, Bingham AL, Eron J,
Frelinger JA. (2002) HIV antigens can induce
TGF-beta(1)-producing immunoregulatory CD8+
T cells. J. Immunol. 168:2247–54.
51. Kelesidis T, Kendall MA, Yang OO, Hodis HN,
Currier JS. (2012) Biomarkers of microbial
translocation and macrophage activation: associ-
ation with progression of subclinical atheroscle-
rosis in HIV-1 infection. J. Infect. Dis. 206:1558–67.
52. Sandler NG, et al. (2011) Plasma levels of soluble
CD14 independently predict mortality in HIV in-
fection. J. Infect. Dis. 203:780–90.
53. Lien E, et al. (1998) Elevated levels of serum-
 soluble CD14 in human immunodeficiency virus
type 1 (HIV-1) infection: correlation to disease
progression and clinical events. Blood. 92:2084–92.
54. Dinarello CA. (2009) Immunological and inflam-
matory functions of the interleukin-1 family.
Annu. Rev. Immunol. 27:519–50.
55. Dinarello CA. (2010) Why not treat human can-
cer with interleukin-1 blockade? Cancer Metasta-
sis Rev. 29:317–29.
56. Zeng Q, et al. (2012) Therapeutic potential of in-
terleukin-37 for suppression of aortic valve in-
flammatory and osteogenic responses. Circula-
tion. 126:A11803.
57. Cassol E, et al. (2010) Persistent microbial translo-
cation and immune activation in HIV-1-infected
South Africans receiving combination antiretrovi-
ral therapy. J. Infect. Dis. 202:723–33.
58. Burdo TH, et al. (2011) Soluble CD163 made by
monocyte/macrophages is a novel marker of
HIV activity in early and chronic infection prior
to and after anti-retroviral therapy. J. Infect. Dis.
204:154–63.
59. Moller HJ. (2012) Soluble CD163. Scand. J. Clin.
Lab. Invest. 72:1–13.
60. Hatano H, et al. (2013) Cell-based measures of
viral persistence are associated with immune ac-
tivation and programmed cell death protein 1
(PD-1)-expressing CD4+ T cells. J. Infect. Dis.
208:50–6.
61. Poizot-Martin I, et al. (2013) Lack of correlation
between the size of HIV proviral DNA reservoir
and the level of immune activation in HIV-in-
fected patients with a sustained undetectable HIV
viral load for 10 years. J. Clin. Virol. 57:351–5.
62. Marchetti G, et al. (2010) Skewed T-cell matura-
tion and function in HIV-infected patients failing
CD4+ recovery upon long-term virologically
suppressive HAART. AIDS. 24:1455–60.
R E S E A R C H  A R T I C L E
M O L  M E D  2 1 : 3 3 7 - 3 4 5 ,  2 0 1 5  |  H Ø J E N  E T  A L .  |  3 4 5
Cite this article as: Højen JF, et al. (2015) Interleukin-37
expression is increased in chronic HIV-1-infected
individuals and is associated with inflammation
and the size of the total viral reservoir. Mol. Med.
21:337–45.
